CULVER CITY, Calif. --(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory
Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer) Phoenix – February 22, 2016 – NantWorks , LLC, NantKwest (Nasdaq: NK), and NantHealth , LLC today announced the scheduled discussion topics
Culver City, California, April 5, 2016 —NantBioScience, Inc., is a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor, independent of the cancer’s anatomical type.
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding Brings Celgene’s Investment to $105M in NantCell Valued at $4 Billion Currently Enrolling Patients in Advanced Stage Trials in 15 Indications for
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 18, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
The NANT Cancer Vaccine, the First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation Personalized Molecular Informed Therapy with NantHealth's GPS Cancer as the Complementary Diagnostic for All Tumor Types A Cancer
by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc . announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc .
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 12, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
Promising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 14, 2016-- NantKwest Inc.
